Abstract
Until recently, due to the limited GH supply, GH therapy has been used only in GH deficiency (GHD). It has been shown that also other short children may benefit fran GH therapy. But there has been no other means except trial to predict the response. It has been shown earlier that there is a rise in serum PIIINP concentration during GH therapy. To evaluate the validity of PIIINP determination in the prediction of the response to GH therapy, we followed diangos in PIIINP for 6 montlis after the onset of GH treatment. The study comprised 12 children, 5 boys and 7 girls, with the mean age of 8.3∓3.8(2.6−16.8) and bone age 5.6∓3.7 (1.2–13) years. In all the relative height was below -2.5SD. Nine were diagnosed GHD (peak GH<7ug/l). The children were treated with biosynthetic GH (provided by Eli Lilly S.A.), given at bed-time, s.c., 0.1U/kg/x3/wk. Blood samples for PIIINP were taken at dg and at 1 wk, 5 wks, 3 and 6 months during the therapy.
Results:After 6 months 5 children were considered non-responders(NR) on the basis of no or insufficient growth velocity acceleration. Therapy was discontinued in them and continued in 7 responders(R). Before the onset of therapy there were no differences in the clinical data between R and NR, but the mean PIIINP was higher in NR than in R (7.6∓2.4 vs 5.4∓1.0 ug/1, p<0.025). There were no differences between R and NR in the mean values of PIIINP during therapy, but there was a difference in die rise of PIIINP after 5 weeks. The rise was higher in R (3.7∓1.2 vs 1.3∓0.9 ug/l, p<0.005). Only in one child whose all PIIINP values were higher than any other values in NR group, the rise of PIIINP fell into the range of R. The more pronounced rise in PIIINP after 5 weeks on GH therapy in responders may help in determing those children who will benefit from long-term GH therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Käär, ML., Tapanainen, P., Knip, M. et al. THE USE OF SERUM AMINOTERMINAL PROPETIDE OF TYPE III PROCOLLAGEN (PSHINP) CONCENTRATION IN PREDICTING THE RESPONSE TO GROWTH HORMONE (GH) THERAPY IN SHORT CHILDREN. Pediatr Res 23, 123 (1988). https://doi.org/10.1203/00006450-198801000-00132
Issue Date:
DOI: https://doi.org/10.1203/00006450-198801000-00132